{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-084520","form_type":"8-K","ticker":"TCRT","cik":"0001107421","company_name":"Alaunos Therapeutics, Inc.","filed_at":"2023-03-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:43.883517+00:00","generated_at":"2026-06-17T08:54:02.586130+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Alaunos Therapeutics appoints Dr. Robert Hofmeister to board, replacing Dr. Christopher Bowden","bullets":["Christopher Bowden resigned from board effective March 30, 2023; no disagreement with company.","Robert Hofmeister appointed as director effective March 30, 2023, filling Bowden's vacancy.","Hofmeister brings over 25 years of T-cell therapy experience; previously CSO at TCR2 Therapeutics.","Hofmeister receives initial option for 150,000 shares and pro-rated annual grant for 16,667 shares.","Hofmeister appointed to Corporate Governance and Nominating and Compensation Committees."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-084520","json":"https://secwatch.observer/filing/0001193125-23-084520.json","markdown":"https://secwatch.observer/filing/0001193125-23-084520.md","text":"https://secwatch.observer/filing/0001193125-23-084520.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1107421/000119312523084520/0001193125-23-084520-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1107421/000119312523084520/d490816d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T08:54:02.586130+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3cfd977632","claim":"Christopher Bowden resigned as Director at Alaunos Therapeutics, Inc..","evidence_excerpt":"Christopher Bowden, M.D. delivered notice of his resignation from the board of directors (the “Board”) of Alaunos Therapeutics, Inc. (the “Company”), effective March 30, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1107421/000119312523084520/0001193125-23-084520-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"7e44e69fa7","claim":"Robert Hofmeister was appointed as Director at Alaunos Therapeutics, Inc..","evidence_excerpt":"the Board appointed Robert Hofmeister, Ph.D., as a director of the Company effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1107421/000119312523084520/0001193125-23-084520-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}